

**Medicaid Preferred Drug List (PDL) Program:
Round 1 Annual Drug Class Review
Pharmacy and Therapeutics Committee Meeting
Monday, September 20, 2004
9:00 a.m., DMAS Board Room
DRAFT AGENDA**

- **Welcome and Introductions** Patrick W. Finnerty, Director
- **Comments from the Secretary of Health and Human Resources** The Honorable Jane H. Woods, Secretary of Health and Human Resources
- **Comments from the Chairperson** Randy Axelrod, M.D., Chairman
- **Open Issues** Patrick W. Finnerty, Director
Randy Axelrod, M.D., Chairman
 - PDL Multisource and Product Availability Policy
 - Long Acting Narcotics Class Discussion
- **Acceptance of Minutes from April 21, 2004 Meeting** P&T Committee Members
- **Drug Class Discussions for Round 1 Annual Review** P&T Committee Members
 - HMG CoA Reductase Inhibitors (Statins)
 - Selective Cox-2 Inhibitors and NSAIDS
 - Proton Pump Inhibitors (PPIs)
 - Angiotensin II Receptor Blocking Agents (ARBs)
 - Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
 - Inhaled Corticosteroids
 - Nasal Steroids
 - Beta Adrenergics
 - Beta Blockers
 - Calcium Channel Blockers
 - H2 Antagonists
 - Second Generation Antihistamines (LSAs)
 - Sedative Hypnotics
- **Confidential Meeting** Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information
- **Criteria Discussions for Round 1 Annual Review** P&T Committee Members
- **P&T Committee Discussion** Randy Axelrod, M.D.
P&T Committee Members
- **Next Meeting – October 6, 2004, 1:00 p.m.** Randy Axelrod, M.D., Chairman